Cerebral Infarction Clinical Trial
— GPS-IPOfficial title:
Prevalence of G6PD Deficiency in Cerebral Infarction Patients and the Correlation With Prognosis in Shaanxi Province
Cerebral infarction brings heavy burden to patients and families with high morbidity, mortality, disability and recurrence rate. Anti-platelet aggregation therapy plays important role for secondary prevention of cerebral infarction. G6PD deficiency is a rare genetic disorder, patients with this disorder could suffer hemolysis after eating broad beans. Professor Zeng Jinsheng et al found that the hemolysis risk of G6PD deficiency patients was significantly increased when aspirin was applied in Guangdong Province. However, the prevalence of G6PD deficiency in northern China remains unknown, as well as the safety of antiplatelet therapy. To this end, 1000 patients with acute cerebral infarction will be continuously included in 30 second-level and above hospitals in 10 prefectures and cities of Shaanxi Province for observation and follow-up for 12 months, to explore the prevalence of G6PD deficiency in cerebral infarction patients in Shaanxi Province, and to analyze the relationship between G6PD deficiency and the clinical characteristics and prognosis of cerebral infarction. To clarify the efficacy and safety of antiplatelet therapy for G6PD patients with cerebral infarction is of great significance for guiding the individualized treatment of cerebral infarction.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - meets the diagnostic criteria of acute cerebral infarction established by Neurology Society of Chinese Medical Association, and confirmed by cranial Magnetic Resonance Imaging; - Time from onset to enrollment =14 days; - Volunteer to participate in the study and sign the informed consent. Exclusion Criteria: - Silent cerebral infarction with no symptoms and signs; - Complicated with post-infarction hemorrhage; - Cerebral hernia and other complications caused by massive cerebral infarction may lead to death in acute phase; - Cardiogenic cerebral embolism caused by atrial fibrillation; - Cerebral infarction caused by tumor, vasculitis and other special reasons; - Complicated with serious systemic diseases, including liver and kidney insufficiency, respiratory failure, heart failure, infection, etc |
Country | Name | City | State |
---|---|---|---|
China | Xi'an Jiatong University | Xi'an | Shaanxi |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital Xi'an Jiaotong University | Simcere Company |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of G6PD deficiency | Prevalence of G6PD deficiency in cerebral infarction patients in Shaanxi Province | up to 24 weeks | |
Secondary | National Institute of Health stroke scale | on a scale of 0-42, the higher the score, the more damage of the nervous system | 1 year | |
Secondary | All-cause mortality rate | All-cause mortality was calculated in % for both groups | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02551003 -
Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
|
Phase 1/Phase 2 | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT00684515 -
Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)
|
Phase 2 | |
Not yet recruiting |
NCT04082091 -
Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
|
||
Completed |
NCT01915368 -
Determining Optimal Post-Stroke Exercise (DOSE)
|
N/A | |
Terminated |
NCT01684462 -
The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke
|
Phase 2 | |
Completed |
NCT00386191 -
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
|
Phase 4 | |
Completed |
NCT00004734 -
Vitamin Therapy for Prevention of Stroke
|
Phase 3 | |
Completed |
NCT02684825 -
Detection of Silent Atrial Fibrillation aFter Ischemic StrOke
|
N/A | |
Completed |
NCT02248233 -
Nimodipine for Treating Acute Massive Cerebral Infarction
|
Phase 4 | |
Completed |
NCT02963545 -
TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke
|
N/A | |
Completed |
NCT02511249 -
Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke
|
N/A | |
Completed |
NCT02101606 -
Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke
|
Phase 2 | |
Completed |
NCT00829361 -
Stroke Telemedicine for Arizona Rural Residents Trial
|
N/A | |
Completed |
NCT01500421 -
Safty and Feasibility Study of Therapeutic Cooling in Acute Ischemic Stroke (COOLAID Øresund)
|
Phase 2 | |
Recruiting |
NCT01003470 -
Treating Apoplectic Sequela With Acupuncture: a Randomized Controlled Study
|
Phase 2 | |
Terminated |
NCT00331890 -
ICTUS Study: International Citicoline Trial on Acute Stroke
|
Phase 3 | |
Not yet recruiting |
NCT04696523 -
Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT03741400 -
Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke
|
N/A |